QQ客服 官方微博 反馈留言

浏览/检索结果: 共6条，第1-6条 帮助 限定条件 专题：中国医学科学院 北京协和医学院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Noninvasive imaging in cancer immunotherapy: The way to precision medicine 期刊论文 2019, 卷号: 466, 页码: 13-22 作者:  Du Yang;  Qi Yafei;  Jin Zhengyu;  Tian Jie 收藏  |  浏览/下载：12/0  |  提交时间：2020/01/03 Cancer  Immune checkpoint inhibitor  Immunotherapy  Molecular imaging  Precision medicine   Myocarditis following the use of different immune checkpoint inhibitor regimens: A real-world analysis of post-marketing surveillance data 期刊论文 2019, 卷号: 76, 页码: 105866 作者:  Fan Qianqian;  Hu Yang;  Yang Changqing;  Zhao Bin 收藏  |  浏览/下载：7/0  |  提交时间：2020/01/03 Adverse drug events  Data mining  Immune checkpoint inhibitors  Myocarditis  Spontaneous reporting system   Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies 期刊论文 2019, 卷号: 12, 期号: 1, 页码: 42 作者:  Wang, Dongxu;  Lin, Jianzhen;  Yang, Xu;  Long, Junyu;  Bai, Yi 收藏  |  浏览/下载：8/0  |  提交时间：2020/01/03 Gastrointestinal malignancies  PD-1/PD-L1 blockade  Immune checkpoint inhibitor  Combination immunotherapy  Clinical application  Rationale  Clinical trial   Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody 期刊论文 2019, 卷号: 10, 期号: 6, 页码: 1395-1401 作者:  Wang, Xi;  Zhang, Bo;  Chen, Xuelian;  Mo, Hongnan;  Wu, Dawei 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/03 Esophageal squamous cell carcinoma  immune checkpoint inhibitor  lactate dehydrogenase  markers  programmed cell death-1   Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis 期刊论文 2018, 卷号: 9, 期号: 10, 页码: 1220-1230 作者:  Tan, Qiaoyun;  Liu, Shuxia;  Liang, Caixia;  Han, Xiaohong;  Shi, Yuankai 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/03 Cancer  immune checkpoint inhibitor  marker  neutrophil to lymphocyte ratio  platelet to lymphocyte ratio   CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises 期刊论文 2018, 卷号: 14, 期号: 21, 页码: 2179-2188 作者:  Tong, Bing;  Wang, Mengzhao 收藏  |  浏览/下载：10/0  |  提交时间：2020/01/03 anti-CD47 monoclonal antibody  bispecific antibody  cancer  CD47  CD47 blockade  immune checkpoint inhibitor  immunotherapy  phagocytosis  SIRP  tumor-associated macrophage